{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:16:17Z","timestamp":1786979777314,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000374","name":"British Medical Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012317","name":"UCLH Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014660","name":"Society for the Study of Addiction","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014660","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"crossref","award":["MR\/V025945\/1"],"award-info":[{"award-number":["MR\/V025945\/1"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>There is growing interest in the therapeutic potential of cannabidiol (CBD) across a range of psychiatric disorders. CBD has been found to reduce anxiety during experimentally induced stress in anxious individuals and healthy controls. However, the mechanisms underlying the putative anxiolytic effects of CBD are unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We sought to investigate the behavioural and neural effects of a single dose of CBD vs. placebo on a range of emotion-related measures to test cognitive-mechanistic models of its effects on anxiety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a randomised, double-blind, placebo-controlled, crossover, acute oral challenge of 600\u00a0mg of CBD in 24 healthy participants on emotional processing, with neuroimaging (viewing emotional faces during functional magnetic resonance imaging) and cognitive (emotional appraisal) measures as well as subjective response to experimentally induced anxiety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CBD did not produce effects on brain responses to emotional faces and cognitive measures of emotional processing, or modulate experimentally induced anxiety, relative to placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Given the rising popularity of CBD for its putative medical benefits, these findings question whether\u00a0further research is warranted to investigate the clinical potential of CBD for the treatment of anxiety disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00213-022-06070-3","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T09:18:10Z","timestamp":1650532690000},"page":"1539-1549","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging study"],"prefix":"10.1007","volume":"239","author":[{"given":"Michael A. P.","family":"Bloomfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeya","family":"Yamamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandni","family":"Hindocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustus P. M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn L. L.","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah R.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Statton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"Wall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel H.","family":"Lees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver D.","family":"Howes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie H.","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan P.","family":"Roiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom P.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,21]]},"reference":[{"key":"6070_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/480161a","volume":"480","author":"A Abbott","year":"2011","unstructured":"Abbott A (2011) Novartis to shut brain research facility. Nature 480:161\u2013162. https:\/\/doi.org\/10.1038\/480161a","journal-title":"Nature"},{"key":"6070_CR2","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00429-005-0025-5","volume":"210","author":"K Amunts","year":"2005","unstructured":"Amunts K et al (2005) Cytoarchitectonic mapping of the human amygdala, hippocampal region and entorhinal cortex: intersubject variability and probability maps. Anat Embryol (Berl) 210:343\u2013352. https:\/\/doi.org\/10.1007\/s00429-005-0025-5","journal-title":"Anat Embryol (Berl)"},{"key":"6070_CR3","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00213-019-05442-6","volume":"237","author":"E Appiah-Kusi","year":"2020","unstructured":"Appiah-Kusi E et al (2020) Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis. Psychopharmacology 237:1121\u20131130. https:\/\/doi.org\/10.1007\/s00213-019-05442-6","journal-title":"Psychopharmacology"},{"key":"6070_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1089\/can.2017.0014","volume":"2","author":"DL Arndt","year":"2017","unstructured":"Arndt DL, de Wit H (2017) Cannabidiol does not dampen responses to emotional stimuli in healthy adults. Cannabis Cannabinoid Res 2:105\u2013113. https:\/\/doi.org\/10.1089\/can.2017.0014","journal-title":"Cannabis Cannabinoid Res"},{"key":"6070_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.drugalcdep.2016.11.030","volume":"172","author":"S Babalonis","year":"2017","unstructured":"Babalonis S, Haney M, Malcolm RJ, Lofwall MR, Votaw VR, Sparenborg S, Walsh SL (2017) Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend 172:9\u201313. https:\/\/doi.org\/10.1016\/j.drugalcdep.2016.11.030","journal-title":"Drug Alcohol Depend"},{"key":"6070_CR6","doi-asserted-by":"publisher","first-page":"d1199","DOI":"10.1136\/bmj.d1199","volume":"342","author":"D Baldwin","year":"2011","unstructured":"Baldwin D, Woods R, Lawson R, Taylor D (2011) Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ 342:d1199. https:\/\/doi.org\/10.1136\/bmj.d1199","journal-title":"BMJ"},{"key":"6070_CR7","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1037\/\/0022-006x.56.6.893","volume":"56","author":"AT Beck","year":"1988","unstructured":"Beck AT, Epstein N, Brown G, Steer RA (1988) An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 56:893\u2013897. https:\/\/doi.org\/10.1037\/\/0022-006x.56.6.893","journal-title":"J Consult Clin Psychol"},{"key":"6070_CR8","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/npp.2011.6","volume":"36","author":"MM Bergamaschi","year":"2011","unstructured":"Bergamaschi MM et al (2011) Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology 36:1219\u20131226. https:\/\/doi.org\/10.1038\/npp.2011.6","journal-title":"Neuropsychopharmacology"},{"key":"6070_CR9","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/npp.2009.184","volume":"35","author":"S Bhattacharyya","year":"2010","unstructured":"Bhattacharyya S et al (2010) Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35:764\u2013774. https:\/\/doi.org\/10.1038\/npp.2009.184","journal-title":"Neuropsychopharmacology"},{"key":"6070_CR10","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/jamapsychiatry.2018.2309","volume":"75","author":"S Bhattacharyya","year":"2018","unstructured":"Bhattacharyya S et al (2018) Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in people at clinical high risk of psychosis: a randomized clinical trial. JAMA Psychiatry 75:1107\u20131117. https:\/\/doi.org\/10.1001\/jamapsychiatry.2018.2309","journal-title":"JAMA Psychiatry"},{"key":"6070_CR11","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.euroneuro.2008.07.001","volume":"18","author":"RM Bitencourt","year":"2008","unstructured":"Bitencourt RM, Pamplona FA, Takahashi RN (2008) Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats. Eur Neuropsychopharmacol 18:849\u2013859. https:\/\/doi.org\/10.1016\/j.euroneuro.2008.07.001","journal-title":"Eur Neuropsychopharmacol"},{"key":"6070_CR12","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","volume":"12","author":"EM Blessing","year":"2015","unstructured":"Blessing EM, Steenkamp MM, Manzanares J, Marmar CR (2015) Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics 12:825\u2013836. https:\/\/doi.org\/10.1007\/s13311-015-0387-1","journal-title":"Neurotherapeutics"},{"key":"6070_CR13","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1177\/0269881120936419","volume":"34","author":"MAP Bloomfield","year":"2020","unstructured":"Bloomfield MAP et al (2020) The effects of acute cannabidiol on cerebral blood flow and its relationship to memory: an arterial spin labelling magnetic resonance imaging study. J Psychopharmacol 34:981\u2013989. https:\/\/doi.org\/10.1177\/0269881120936419","journal-title":"J Psychopharmacol"},{"key":"6070_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00213-008-1168-x","volume":"199","author":"AC Campos","year":"2008","unstructured":"Campos AC, Guimaraes FS (2008) Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology (Berl) 199:223\u2013230. https:\/\/doi.org\/10.1007\/s00213-008-1168-x","journal-title":"Psychopharmacology (Berl)"},{"key":"6070_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/fbp.0b013e32833b33c5","volume":"21","author":"PC Casarotto","year":"2010","unstructured":"Casarotto PC, Gomes FV, Resstel LB, Guimaraes FS (2010) Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors. Behav Pharmacol 21:353\u2013358. https:\/\/doi.org\/10.1097\/fbp.0b013e32833b33c5","journal-title":"Behav Pharmacol"},{"key":"6070_CR16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.drugalcdep.2010.01.012","volume":"109","author":"N Constantinou","year":"2010","unstructured":"Constantinou N, Morgan CJ, Battistella S, O\u2019Ryan D, Davis P, Curran HV (2010) Attentional bias, inhibitory control and acute stress in current and former opiate addicts. Drug Alcohol Depend 109:220\u2013225. https:\/\/doi.org\/10.1016\/j.drugalcdep.2010.01.012","journal-title":"Drug Alcohol Depend"},{"key":"6070_CR17","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00213-012-2955-y","volume":"226","author":"RK Das","year":"2013","unstructured":"Das RK et al (2013) Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology 226:781\u2013792. https:\/\/doi.org\/10.1007\/s00213-012-2955-y","journal-title":"Psychopharmacology"},{"key":"6070_CR18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/0269881119895536","volume":"34","author":"SM de Faria","year":"2020","unstructured":"de Faria SM et al (2020) Effects of acute cannabidiol administration on anxiety and tremors induced by a simulated public speaking test in patients with Parkinson\u2019s disease. J Psychopharmacol 34:189\u2013196. https:\/\/doi.org\/10.1177\/0269881119895536","journal-title":"J Psychopharmacol"},{"key":"6070_CR19","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.neuroimage.2004.12.034","volume":"25","author":"SB Eickhoff","year":"2005","unstructured":"Eickhoff SB, Stephan KE, Mohlberg H, Grefkes C, Fink GR, Amunts K, Zilles K (2005) A new SPM toolbox for combining probabilistic cytoarchitectonic maps and functional imaging data. Neuroimage 25:1325\u20131335. https:\/\/doi.org\/10.1016\/j.neuroimage.2004.12.034","journal-title":"Neuroimage"},{"key":"6070_CR20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3758\/bf03193146","volume":"39","author":"F Faul","year":"2007","unstructured":"Faul F, Erdfelder E, Lang AG, Buchner A (2007) G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39:175\u2013191. https:\/\/doi.org\/10.3758\/bf03193146","journal-title":"Behav Res Methods"},{"key":"6070_CR21","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S2215-0366(20)30290-X","volume":"7","author":"TP Freeman","year":"2020","unstructured":"Freeman TP et al (2020) Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry 7:865\u2013874. https:\/\/doi.org\/10.1016\/S2215-0366(20)30290-X","journal-title":"Lancet Psychiatry"},{"key":"6070_CR22","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1017\/S1461145709990617","volume":"13","author":"P Fusar-Poli","year":"2010","unstructured":"Fusar-Poli P et al (2010) Modulation of effective connectivity during emotional processing by delta 9-tetrahydrocannabinol and cannabidiol. Int J Neuropsychopharmacol 13:421\u2013432. https:\/\/doi.org\/10.1017\/S1461145709990617","journal-title":"Int J Neuropsychopharmacol"},{"key":"6070_CR23","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1001\/archgenpsychiatry.2008.519","volume":"66","author":"P Fusar-Poli","year":"2009","unstructured":"Fusar-Poli P et al (2009) Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 66:95\u2013105. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2008.519","journal-title":"Arch Gen Psychiatry"},{"key":"6070_CR24","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/BF02244012","volume":"100","author":"FS Guimaraes","year":"1990","unstructured":"Guimaraes FS, Chiaretti TM, Graeff FG, Zuardi AW (1990) Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology 100:558\u2013559. https:\/\/doi.org\/10.1007\/BF02244012","journal-title":"Psychopharmacology"},{"key":"6070_CR25","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1038\/npp.2015.367","volume":"41","author":"M Haney","year":"2016","unstructured":"Haney M et al (2016) Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis. Neuropsychopharmacology 41:1974\u20131982. https:\/\/doi.org\/10.1038\/npp.2015.367","journal-title":"Neuropsychopharmacology"},{"key":"6070_CR26","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/j.1360-0443.1991.tb01879.x","volume":"86","author":"TF Heatherton","year":"1991","unstructured":"Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO (1991) The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86:1119\u20131127. https:\/\/doi.org\/10.1111\/j.1360-0443.1991.tb01879.x","journal-title":"Br J Addict"},{"key":"6070_CR27","doi-asserted-by":"publisher","first-page":"451","DOI":"10.2174\/187152709789824624","volume":"8","author":"MN Hill","year":"2009","unstructured":"Hill MN, Gorzalka BB (2009) The endocannabinoid system and the treatment of mood and anxiety disorders. CNS Neurol Disord Drug Targets 8:451\u2013458. https:\/\/doi.org\/10.2174\/187152709789824624","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"6070_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/add.14243","author":"C Hindocha","year":"2018","unstructured":"Hindocha C et al (2018) Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal. Addiction. https:\/\/doi.org\/10.1111\/add.14243","journal-title":"Addiction"},{"key":"6070_CR29","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.euroneuro.2014.11.014","volume":"25","author":"C Hindocha","year":"2015","unstructured":"Hindocha C, Freeman TP, Schafer G, Gardener C, Das RK, Morgan CJ, Curran HV (2015) Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users. Eur Neuropsychopharmacol 25:325\u2013334. https:\/\/doi.org\/10.1016\/j.euroneuro.2014.11.014","journal-title":"Eur Neuropsychopharmacol"},{"key":"6070_CR30","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.neuropharm.2011.08.013","volume":"62","author":"YT Hsiao","year":"2012","unstructured":"Hsiao YT, Yi PL, Li CL, Chang FC (2012) Effect of cannabidiol on sleep disruption induced by the repeated combination tests consisting of open field and elevated plus-maze in rats. Neuropharmacology 62:373\u2013384. https:\/\/doi.org\/10.1016\/j.neuropharm.2011.08.013","journal-title":"Neuropharmacology"},{"key":"6070_CR31","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1177\/0269881117737400","volume":"32","author":"H Hundal","year":"2018","unstructured":"Hundal H et al (2018) The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group. J Psychopharmacol 32:276\u2013282. https:\/\/doi.org\/10.1177\/0269881117737400","journal-title":"J Psychopharmacol"},{"key":"6070_CR32","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1176\/appi.ajp.2019.18101191","volume":"176","author":"YL Hurd","year":"2019","unstructured":"Hurd YL et al (2019) Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial. Am J Psychiatry 176:911\u2013922. https:\/\/doi.org\/10.1176\/appi.ajp.2019.18101191","journal-title":"Am J Psychiatry"},{"key":"6070_CR33","unstructured":"Inc. S (Released 2020.) IBM SPSS Statistics for Macintosh, Version 27.0"},{"key":"6070_CR34","doi-asserted-by":"crossref","unstructured":"Jeffreys H (1998) The theory of probability. OUP Oxford,","DOI":"10.1093\/oso\/9780198503682.001.0001"},{"issue":"Suppl 11","key":"6070_CR35","doi-asserted-by":"publisher","first-page":"S467","DOI":"10.1002\/acr.20561","volume":"63","author":"LJ Julian","year":"2011","unstructured":"Julian LJ (2011) Measures of anxiety: State-Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale-Anxiety (HADS-A). Arthritis Care Res (Hoboken) 63(Suppl 11):S467-472. https:\/\/doi.org\/10.1002\/acr.20561","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"6070_CR36","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1177\/0269881120944148","volume":"34","author":"W Lawn","year":"2020","unstructured":"Lawn W et al (2020) The acute effects of cannabidiol on the neural correlates of reward anticipation and feedback in healthy volunteers. J Psychopharmacol 34:969\u2013980. https:\/\/doi.org\/10.1177\/0269881120944148","journal-title":"J Psychopharmacol"},{"key":"6070_CR37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1590\/1516-4446-2017-0015","volume":"41","author":"IM Linares","year":"2019","unstructured":"Linares IM, Zuardi AW, Pereira LC, Queiroz RH, Mechoulam R, Guimaraes FS, Crippa JA (2019) Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test Braz J. Psychiatry 41:9\u201314. https:\/\/doi.org\/10.1590\/1516-4446-2017-0015","journal-title":"Psychiatry"},{"key":"6070_CR38","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cpr.2015.08.004","volume":"42","author":"AG Loerinc","year":"2015","unstructured":"Loerinc AG, Meuret AE, Twohig MP, Rosenfield D, Bluett EJ, Craske MG (2015) Response rates for CBT for anxiety disorders: need for standardized criteria. Clin Psychol Rev 42:72\u201382. https:\/\/doi.org\/10.1016\/j.cpr.2015.08.004","journal-title":"Clin Psychol Rev"},{"key":"6070_CR39","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/nrn4036","volume":"16","author":"B Lutz","year":"2015","unstructured":"Lutz B, Marsicano G, Maldonado R, Hillard CJ (2015) The endocannabinoid system in guarding against fear, anxiety and stress. Nat Rev Neurosci 16:705\u2013718. https:\/\/doi.org\/10.1038\/nrn4036","journal-title":"Nat Rev Neurosci"},{"key":"6070_CR40","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.3389\/fpsyg.2019.02466","volume":"10","author":"N Masataka","year":"2019","unstructured":"Masataka N (2019) Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders. Front Psychol 10:2466. https:\/\/doi.org\/10.3389\/fpsyg.2019.02466","journal-title":"Front Psychol"},{"key":"6070_CR41","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1126\/science.329.5991.502","volume":"329","author":"G Miller","year":"2010","unstructured":"Miller G (2010) Is pharma running out of brainy ideas? Science 329:502\u2013504. https:\/\/doi.org\/10.1126\/science.329.5991.502","journal-title":"Science"},{"key":"6070_CR42","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.pnpbp.2006.06.004","volume":"30","author":"FA Moreira","year":"2006","unstructured":"Moreira FA, Aguiar DC, Guimaraes FS (2006) Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Prog Neuropsychopharmacol Biol Psychiatry 30:1466\u20131471. https:\/\/doi.org\/10.1016\/j.pnpbp.2006.06.004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"6070_CR43","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1162\/jocn_a_00055","volume":"23","author":"EJ O'Nions","year":"2011","unstructured":"O\u2019Nions EJ, Dolan RJ, Roiser JP (2011) Serotonin transporter genotype modulates subgenual response to fearful faces using an incidental task. J Cogn Neurosci 23:3681\u20133693. https:\/\/doi.org\/10.1162\/jocn_a_00055","journal-title":"J Cogn Neurosci"},{"key":"6070_CR44","unstructured":"Organization WH (2017) Depression and other common mental disorders: global health estimates. https:\/\/apps.who.int\/iris\/handle\/10665\/254610"},{"key":"6070_CR45","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jad.2011.11.014","volume":"140","author":"DA Revicki","year":"2012","unstructured":"Revicki DA et al (2012) Humanistic and economic burden of generalized anxiety disorder in North America and Europe. J Affect Disord 140:103\u2013112. https:\/\/doi.org\/10.1016\/j.jad.2011.11.014","journal-title":"J Affect Disord"},{"key":"6070_CR46","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/0269881111408958","volume":"26","author":"S Ruehle","year":"2012","unstructured":"Ruehle S, Rey AA, Remmers F, Lutz B (2012) The endocannabinoid system in anxiety, fear memory and habituation. J Psychopharmacol 26:23\u201339. https:\/\/doi.org\/10.1177\/0269881111408958","journal-title":"J Psychopharmacol"},{"key":"6070_CR47","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/j.1360-0443.1993.tb02093.x","volume":"88","author":"JB Saunders","year":"1993","unstructured":"Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M (1993) Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption\u2014II. Addiction 88:791\u2013804. https:\/\/doi.org\/10.1111\/j.1360-0443.1993.tb02093.x","journal-title":"Addiction"},{"key":"6070_CR48","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/npp.2017.166","volume":"43","author":"S Selvaraj","year":"2018","unstructured":"Selvaraj S et al (2018) Effect of citalopram on emotion processing in humans: a combined 5-HT1A [(11)C]CUMI-101 PET and functional MRI study. Neuropsychopharmacology 43:655\u2013664. https:\/\/doi.org\/10.1038\/npp.2017.166","journal-title":"Neuropsychopharmacology"},{"key":"6070_CR49","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s40263-018-0578-5","volume":"32","author":"L Taylor","year":"2018","unstructured":"Taylor L, Gidal B, Blakey G, Tayo B, Morrison G (2018) A phase i, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs 32:1053\u20131067. https:\/\/doi.org\/10.1007\/s40263-018-0578-5","journal-title":"CNS Drugs"},{"key":"6070_CR50","unstructured":"Team J (2020) JASP (Version 0.14)[Computer software]."},{"key":"6070_CR51","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.psychres.2008.05.006","volume":"168","author":"N Tottenham","year":"2009","unstructured":"Tottenham N et al (2009) The NimStim set of facial expressions: judgments from untrained research participants. Psychiatry Res 168:242\u2013249. https:\/\/doi.org\/10.1016\/j.psychres.2008.05.006","journal-title":"Psychiatry Res"},{"key":"6070_CR52","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/026988119300700112","volume":"7","author":"AW Zuardi","year":"1993","unstructured":"Zuardi AW, Cosme RA, Graeff FG, Guimaraes FS (1993) Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 7:82\u201388. https:\/\/doi.org\/10.1177\/026988119300700112","journal-title":"J Psychopharmacol"},{"key":"6070_CR53","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3389\/fphar.2017.00259","volume":"8","author":"AW Zuardi","year":"2017","unstructured":"Zuardi AW, Rodrigues NP, Silva AL, Bernardo SA, Hallak JEC, Guimaraes FS, Crippa JAS (2017) Inverted u-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharmacol 8:259. https:\/\/doi.org\/10.3389\/fphar.2017.00259","journal-title":"Front Pharmacol"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-022-06070-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-022-06070-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-022-06070-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T04:10:04Z","timestamp":1700453404000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-022-06070-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,21]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["6070"],"URL":"https:\/\/doi.org\/10.1007\/s00213-022-06070-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.12.11.421776","asserted-by":"object"}]},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,21]]},"assertion":[{"value":"8 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr Bloomfield has participated at an advisory board for Makara Health. Otherwise, the authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}